The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial
NCT ID: NCT02208596
Last Updated: 2014-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
150 participants
INTERVENTIONAL
2014-09-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair After Induced Abortion
NCT06546397
Paracervical Block in First Trimester Surgical Abortions
NCT00617097
Use of an Algorithm to Determine IV Sedation Dosing During First-trimester Surgical Abortion
NCT01994317
Remimazolam Versus Propofol for Painless Abortion
NCT05635955
Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section
NCT03144401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
pentazocine
Every patient enrolled in the study will be given 15 mg pentazocine before induction.
propofol
Etomidate
Group B
In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
pentazocine
Every patient enrolled in the study will be given 15 mg pentazocine before induction.
propofol
Etomidate
Group C
In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
pentazocine
Every patient enrolled in the study will be given 15 mg pentazocine before induction.
propofol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pentazocine
Every patient enrolled in the study will be given 15 mg pentazocine before induction.
propofol
Etomidate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiology (ASA) Physical Status: Ⅰ or Ⅱ
* Singleton pregnancy and the gestational period is 6 to 8 weeks
* Expected operation duration is within 60 minutes
* The body weight should be within 15% around the standard weight
* Signed informed consent form
Exclusion Criteria
* Upper respiratory infections within 4 weeks
* Long use of hormone or history of adrenal suppression
* History of use of glucocorticoids, aprotinin or immunosuppressant
* Manifestation of immunodeficiency
* History of use of sedatives or opiates
* Needs of Neuromuscular blocker (except intubation)
* Allergy to trial drug or other contraindication
* Pregnant or breast-feeding women
* Attended other trial past 30 days
20 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Affiliated Hospital of Zhengzhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20140729
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.